MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.
How? 🤔
The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.
An upcoming Phase 2a trial will put the compound to the test.
